BioMark Diagnostics Inc (BUX) - Product Pipeline Analysis, 2019 Update

Summary

BioMark Diagnostics Inc (BioMark Diagnostics) is an oncology-focused medical equipment company that owns and develops multiple intellectual properties in detection and quantitation of metabolites. The company’s advanced near-to- market diagnostic technologies designed to improve patient outcomes. Its products include cancer diagnostic tools, Amantadine, cancer management solutions, biomarkers and others. BioMark Diagnostics offers services such as science of metabolomics research and development, research and technology development, clinical trials, non-imaging cancer detection assays, cell-signaling pathways and others. The company’s products are used in the treatment of cancers including lung, breast, prostate, and GI cancers. BioMark Diagnostics is headquartered in Richmond, British Columbia, Canada.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company BioMark Diagnostics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:


- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company
 


BioMark Diagnostics Inc Company Overview
BioMark Diagnostics Inc Company Snapshot
BioMark Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
BioMark Diagnostics Inc – Pipeline Analysis Overview
BioMark Diagnostics Inc - Key Facts
BioMark Diagnostics Inc - Major Products and Services
BioMark Diagnostics Inc Pipeline Products by Development Stage
BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
BioMark Diagnostics Inc Pipeline Products Overview
Biomarker Assay - Ovarian Cancer
Biomarker Assay - Ovarian Cancer Product Overview
Metabolomics-based Diagnostic Assay - Breast Cancer
Metabolomics-based Diagnostic Assay - Breast Cancer Product Overview
Metabolomics-based Diagnostic Assay - Cervical Cancer
Metabolomics-based Diagnostic Assay - Cervical Cancer Product Overview
Metabolomics-based Diagnostic Assay - Colorectal Cancer
Metabolomics-based Diagnostic Assay - Colorectal Cancer Product Overview
Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer
Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer Product Overview
Metabolomics-based Diagnostic Assay - Lung Cancer
Metabolomics-based Diagnostic Assay - Lung Cancer Product Overview
Metabolomics-based Diagnostic Assay - Lung Cancer Clinical Trial
Metabolomics-Based Diagnostic Assay - Melanoma
Metabolomics-Based Diagnostic Assay - Melanoma Product Overview
Metabolomics-based Diagnostic Assay - Prostate Cancer
Metabolomics-based Diagnostic Assay - Prostate Cancer Product Overview
POC Device - Monoclonal Antibodies
POC Device - Monoclonal Antibodies Product Overview
SSAT-Amantadine Assay - ELISA KIT
SSAT-Amantadine Assay - ELISA KIT Product Overview
SSAT-Amantadine Assay - Raman SERS
SSAT-Amantadine Assay - Raman SERS Product Overview
SSAT1 - Acetylamantadine Assay
SSAT1 - Acetylamantadine Assay Product Overview
BioMark Diagnostics Inc - Key Competitors
BioMark Diagnostics Inc - Key Employees
BioMark Diagnostics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
BioMark Diagnostics Inc, Recent Developments
May 30, 2019: Biomark announces new patent granted in United States
Apr 17, 2019: Biomark and its team of collaborators secure CHRP funding
Mar 12, 2019: BioMark Announces New Patent Granted in China
Mar 29, 2016: BioMark Receives Approval for Its Lung Cancer Treatment Protocol
Feb 16, 2016: BioMark Announces Progress Towards Data Analysis
Sep 10, 2015: BioMark Diagnostics to Conduct Validation Studies for Its Patented Assays in Patients With Lung Cancer
Sep 09, 2015: BioMark Diagnostics Receives Clearance From Health Canada to Commence Clinical Trial With Patented Non-Invasive, Urine-Based Assay to Measure Response to Treatment for Lung Cancer
Aug 19, 2015: BioMark Diagnostics Announces Progress in Assay Validation for Clinical Sample Analysis
Aug 13, 2015: BioMark Diagnostics Unveils U.S. Strategy
Aug 11, 2015: BioMark Appoints Dr. Thomas Malcolm to Lead U.S. Operations
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


BioMark Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
BioMark Diagnostics Inc Pipeline Products by Equipment Type
BioMark Diagnostics Inc Pipeline Products by Indication
BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
BioMark Diagnostics Inc, Key Facts
BioMark Diagnostics Inc, Major Products and Services
BioMark Diagnostics Inc Number of Pipeline Products by Development Stage
BioMark Diagnostics Inc Pipeline Products Summary by Development Stage
BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
BioMark Diagnostics Inc Ongoing Clinical Trials Summary
Biomarker Assay - Ovarian Cancer - Product Status
Biomarker Assay - Ovarian Cancer - Product Description
Metabolomics-based Diagnostic Assay - Breast Cancer - Product Status
Metabolomics-based Diagnostic Assay - Breast Cancer - Product Description
Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Status
Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Description
Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Status
Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Description
Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer - Product Status
Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer - Product Description
Metabolomics-based Diagnostic Assay - Lung Cancer - Product Status
Metabolomics-based Diagnostic Assay - Lung Cancer - Product Description
Metabolomics-based Diagnostic Assay - Lung Cancer - Clinical Trial with Patented Non-invasive, Urine-based Assay to Measure Response to Treatment for Lung Cancer
Metabolomics-Based Diagnostic Assay - Melanoma - Product Status
Metabolomics-Based Diagnostic Assay - Melanoma - Product Description
Metabolomics-based Diagnostic Assay - Prostate Cancer - Product Status
Metabolomics-based Diagnostic Assay - Prostate Cancer - Product Description
POC Device - Monoclonal Antibodies - Product Status
POC Device - Monoclonal Antibodies - Product Description
SSAT-Amantadine Assay - ELISA KIT - Product Status
SSAT-Amantadine Assay - ELISA KIT - Product Description
SSAT-Amantadine Assay - Raman SERS - Product Status
SSAT-Amantadine Assay - Raman SERS - Product Description
SSAT1 - Acetylamantadine Assay - Product Status
SSAT1 - Acetylamantadine Assay - Product Description
BioMark Diagnostics Inc, Key Employees
BioMark Diagnostics Inc, Other Locations
Glossary
 


List Of Figures


BioMark Diagnostics Inc Pipeline Products by Equipment Type
BioMark Diagnostics Inc Pipeline Products by Development Stage
BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
 


Global Cancer Biomarker Market Research Report

Cancer biomarkers are biological molecule found in blood, other body fluids, or tissues and are indicative of the presence of cancer in the body. In the context of China-US trade

USD View Report

Global Cardiac Biomarker Diagnostic Kits Market Research Report

In the context of China-US trade war and COVID-19 epidemic, it will have a big influence on this market. Cardiac Biomarker Diagnostic Kits Report by Material, Application, and Geography

USD View Report

GenMark Diagnostics Inc (GNMK) - Product Pipeline Analysis, 2021 Update

GenMark Diagnostics Inc (GenMark) is a medical device company that provides clinical testing systems. The company offers products such as XT-8 systems and ePlex systems. It offers pipeline products include

USD 750 View Report

XCR Diagnostics Inc - Product Pipeline Analysis, 2020 Update

XCR Diagnostics Inc (XCR Diagnostics) is a designer and developer of real-time PCR assays. The companys products include brucella abortus detection assay, brucella ovis detection assay and custom real time

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available